Valnoctamide

Cat. No.: HY-121877

CAS No.: 4171-13-5

Molecular Formula: $C_8H_{17}NO$

Molecular Weight: 143.23

Target: GABA Receptor

Pathway: Membrane Transporter/Ion Channel; Neuronal Signaling

Storage:

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (698.18 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	6.9818 mL	34.9089 mL	69.8178 mL
5 mM	1.3964 mL	6.9818 mL	13.9636 mL
10 mM	0.6982 mL	3.4909 mL	6.9818 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (17.45 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (17.45 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (17.45 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Valnoctamide (Valmethamide), a derivative of valproate, suppresses benzodiazepine-refractory status epilepticus. Valnoctamide (Valmethamide) acts directly on $GABA_A$ receptors[1].

IC_{50} & Target

$GABA_A$ receptor[1]

CUSTOMER VALIDATION

- Int J Mol Sci. 2019 Sep 17;20(18):4587.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Spampanato J, et al. Valnoctamide enhances phasic inhibition: a potential target mechanism for the treatment of benzodiazepine-refractory status epilepticus. Epilepsia. 2014 Sep;55(9):e94-8.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA